Adicet Bio, Inc. Current Income Tax Expense (Benefit)
Adicet Bio, Inc. (ACET) reported Current Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-12
- Adicet Bio, Inc. current income tax expense (benefit) for fiscal 2025 was $0.00.
- Adicet Bio, Inc. current income tax expense (benefit) for fiscal 2024 was $0.00.
- Adicet Bio, Inc. current income tax expense (benefit) for fiscal 2023 was $0.00.
- Adicet Bio, Inc. current income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Current Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-06 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-19 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-15 |
| 2020-12-31 | -$2.57M 10-K · filed 2022-03-15 |
| 2019-12-31 | $19.00K 10-K · filed 2021-03-12 |
| 2018-12-31 | -$589.00K 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |